DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $687,130 | +4.9% | 2,769 | +1.5% | 0.14% | +2.3% |
Q2 2023 | $655,058 | -3.2% | 2,729 | +1.6% | 0.13% | -5.0% |
Q1 2023 | $677,035 | -3.3% | 2,686 | +1.9% | 0.14% | -5.4% |
Q4 2022 | $699,936 | +15.1% | 2,637 | +12.0% | 0.15% | -3.3% |
Q3 2022 | $608,000 | +2.4% | 2,354 | +0.5% | 0.15% | +10.1% |
Q2 2022 | $594,000 | -11.5% | 2,343 | +2.4% | 0.14% | +5.3% |
Q1 2022 | $671,000 | -14.4% | 2,289 | -3.9% | 0.13% | -10.2% |
Q4 2021 | $784,000 | +27.5% | 2,383 | +18.0% | 0.15% | +16.7% |
Q3 2021 | $615,000 | +13.7% | 2,020 | +0.2% | 0.13% | +13.5% |
Q2 2021 | $541,000 | +21.3% | 2,015 | +1.7% | 0.11% | +15.6% |
Q1 2021 | $446,000 | +4.9% | 1,982 | +3.6% | 0.10% | -8.6% |
Q4 2020 | $425,000 | – | 1,913 | +5.4% | 0.10% | – |
Q3 2020 | $0 | -100.0% | 1,815 | -0.3% | 0.00% | -100.0% |
Q2 2020 | $322,000 | +60.2% | 1,820 | +25.3% | 0.10% | +31.9% |
Q1 2020 | $201,000 | -10.7% | 1,453 | -0.9% | 0.07% | +12.5% |
Q4 2019 | $225,000 | +12.5% | 1,466 | +5.5% | 0.06% | -20.0% |
Q3 2019 | $200,000 | – | 1,390 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |